Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "immuno"

769 News Found

Novo Medi Sciences unveils India’s next-generation varicella vaccine NEXIPOX PLUS
R&D | January 24, 2026

Novo Medi Sciences unveils India’s next-generation varicella vaccine NEXIPOX PLUS

This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues


Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline
News | January 23, 2026

Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline

The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025


Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
News | January 23, 2026

Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance


AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
Clinical Trials | January 20, 2026

AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial

Improvements were also seen in complete response rates, duration of response, and time to next treatment


Syngene locks in Bristol Myers Squibb alliance through 2035
News | January 20, 2026

Syngene locks in Bristol Myers Squibb alliance through 2035

The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle


Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy
News | January 17, 2026

Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy

LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates


Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer
Clinical Trials | January 17, 2026

Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer


Biocon completes Rs. 4,150 crore equity fundraise through QIP
News | January 15, 2026

Biocon completes Rs. 4,150 crore equity fundraise through QIP

The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited